Advertisement

Digestive Diseases and Sciences

, Volume 52, Issue 11, pp 2934–2941 | Cite as

Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up

  • Giuseppe Comparato
  • Libera Fanigliulo
  • Lucas G Cavallaro
  • Giovanni Aragona
  • Giulia Martina Cavestro
  • Veronica Iori
  • Marta Maino
  • Giancarlo Mazzocchi
  • Pierantonio Muzzetto
  • Giancarlo Colla
  • Mario Sianesi
  • Angelo Franzé
  • Francesco Di. Mario
Original Paper

Abstract

In uncomplicated diverticular disease, treatment is aimed at relieving symptoms. The aim of the present study was to evaluate the efficacy of mesalazine for symptomatic relief of uncomplicated diverticular disease of the colon. Two hundred sixty-eight consecutive eligible outpatients (122 male, 146 female; age, 66.1 years; range, 31–81 years) were enrolled in four treatment schedules in a randomized fashion: Group R1 (66 patients), rifaximin, 200 mg bid; Group R2 (69 patients), rifaximin, 400 mg bid; Group M1 (67 patients), mesalazine, 400 mg bid; and Group M2 (66 patients), mesalazine, 800 mg bid. Treatments were administered for 10 days every month for 12 months. Clinical evaluations were performed at admission and at 3-month intervals for 12 months considering 12 clinical variables (upper and lower abdominal pain/discomfort, tenesmus, diarrhea, abdominal tenderness, fever, bloating, general illness, nausea, emesis, dysuria, bleeding) graded as 0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe. The Global Symptomatic Score (GSS) was calculated using the sum of each symptom score. Two hundred forty-four patients completed the 12- month study; 24 were discontinued (14 treated with rifaximin and 10 treated with mesalazine) either as voluntary dropouts or because they developed side effects and/or complications. Group M2 demonstrated a lower frequency of many symptoms after 6 and 12 months of treatment; the mean GSS was significantly lower in Group M2 after 6 and 12 months of therapy by both intention-to-treat and per-protocol analyses. Patients treated with mesalazine (Groups M1+M2) had a lower GSS than subjects treated with rifaximin (Groups R1+R2) during the 12-month follow-up period. We conclude that cyclic administration of mesalazine is effective for symptomatic relief of uncomplicated diverticular disease of the colon. Some symptoms showed greater improvement with mesalazine, 800 mg bid, than with the other treatment schedules.

Keywords

Diverticular disease Diverticula Mesalazine 

Notes

Acknowledgment

This work was conducted under the auspices of the Roberto Farini Foundation for Gastroenterological Research.

References

  1. 1.
    Stollman NH, Baskin JB, for and on behalf of the Ad Hoc Practice Parameters Committee of the American College of Gastroenterology (1999) Diagnosis and management of diverticular disease of the colon in adults. Practice guidelines. Am J Gastroenterol 94(11):3110–3121PubMedCrossRefGoogle Scholar
  2. 2.
    Salzman H, Dustin L (2005) Diverticular disease: diagnosis and treatment. Am Fam Phys 72(7):1230–1234Google Scholar
  3. 3.
    Almy TP, Howell DA (1980) Diverticular disease of the colon. N Engl J Med 302:324–331PubMedCrossRefGoogle Scholar
  4. 4.
    Kohler L, Sauerland S, Neugebauer E, for the Scientific Committee of the European Association for Endoscopic Surgery (1999) Diagnosis and treatment of diverticular disease. Results of a consensus development conference. Surg Endosc 13:430–436PubMedCrossRefGoogle Scholar
  5. 5.
    Schwartz JT, Graham DY (1998) Diverticular disease of the large intestine. In: Diseases of the colon, rectum and anal canal. Kirsner J, Shorter R (eds). Williams & Wilkins, Baltimore, pp 519–536Google Scholar
  6. 6.
    Naitove A, Smith RE (1993) Diverticular disease of the colon. In: Gastrointestinal disease, 5th ed. Sleisenger MH, Fordtran TS (eds). Saunders, Philadelphia, pp 1347–1363Google Scholar
  7. 7.
    Aldoori WH, Giovannucci EL, Rockett HR, et al. (1998) A prospective study of dietary fiber types and symptomatic diverticular disease in men. J Nutr 128:714–719PubMedGoogle Scholar
  8. 8.
    Brodribb AJ (1977) Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet 1(8013):664–666PubMedCrossRefGoogle Scholar
  9. 9.
    Ewerth S, Ahlberg J, Holmstrom B, Persson U, Uden R (1980) Influence on symptoms and transit time of Vi SiblinR in diverticular disease. Acta Chir Scand 500:40–59Google Scholar
  10. 10.
    Solotoft J, Gudmand-Hoyer E, Krag B, Kristensen E, Wulff HR (1976) A double blind trial of wheat bran on symptoms of irritable bowel syndrome. Lancet 1(7954):270–272CrossRefGoogle Scholar
  11. 11.
    Fric P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15(3):313–315PubMedCrossRefGoogle Scholar
  12. 12.
    Papi C, Ciaco A, Koch M, et al. (1995) Efficacy of rifaximine in the treatmentof symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9:33–39PubMedCrossRefGoogle Scholar
  13. 13.
    Latella G, Pimpo MT, Sottili S, et al. (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55–62PubMedCrossRefGoogle Scholar
  14. 14.
    Stollman N, Raskin JB (2004) Diverticular disease of the colon. Lancet 363:631–639PubMedCrossRefGoogle Scholar
  15. 15.
    Bassotti G, Chistolini F, Morelli A (2003) Pathophysiological aspects of diverticular disease of colon and role of large bowel motilità. World J Gastroenterol 9(10):2140–2142PubMedGoogle Scholar
  16. 16.
    Simpson J, Scholefield JH, Spiller RC (2002) Pathogenesis of colonic diverticula. Br J Surgery 89:546–554CrossRefGoogle Scholar
  17. 17.
    Bode MK, Karttunen TJ, Makela J, et al. (2000) Type I and III collagens in human colon cancer and diverticulosis. Scand J Gastroenterol 35:747–752PubMedCrossRefGoogle Scholar
  18. 18.
    Painter NS, Burkitt DP (1975) Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol 4:3–21PubMedGoogle Scholar
  19. 19.
    Ghorai S, Ulbright TM, Douglas K, et al. (2003) Endoscopic findings of diverticular inflammation in colonscopy patients with clinical acute diverticulitis: prevalence and endoscopic spectrum. Am J Gastroenterol 98(4):76–84CrossRefGoogle Scholar
  20. 20.
    Makapugay LM, Dean PJ (1996) Diverticular disease-associated chronic colitis. Am J Surg Pathol 20(1):94–102PubMedCrossRefGoogle Scholar
  21. 21.
    Peppercorn MA (2004) The overlap of inflammatory bowel disease and diverticular disease. J Clin Gastroenterol 38 (Suppl 1):S8–S10PubMedCrossRefGoogle Scholar
  22. 22.
    Sheperd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802CrossRefGoogle Scholar
  23. 23.
    Tursi A (2005) Mesalazine for diverticular disease of the colon-a new role for an old drug. Expert Opin Pharmacother 6(1):69–74PubMedCrossRefGoogle Scholar
  24. 24.
    Eliakim R, Rachmilewitz D (1992) Potenzial mediators in inflammatory bowel disease. Gastroenterol Int 5:48–56Google Scholar
  25. 25.
    Grisham MB (1994) Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859–861PubMedCrossRefGoogle Scholar
  26. 26.
    Wood AJJ (1996) Inflammatory bowel disease. N Engl J Med 334:841–848CrossRefGoogle Scholar
  27. 27.
    Goncalves E, Almeida LM, Dinis TC (1998) Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: A synergistic interaction? Free Rad Res 29:53–66CrossRefGoogle Scholar
  28. 28.
    Gore S, Sheperd NA, Wilkinson SP (1992) Endoscopic crescentic fold disease of the sigmoid colon: the clinical and hystopathological spectrum of a distinctive endoscopic appearance. Int J Colorect Dis 7:76–81CrossRefGoogle Scholar
  29. 29.
    Tursi A (2004) Diverticular disease of the colon. Lancet 363:1397–1398PubMedCrossRefGoogle Scholar
  30. 30.
    Peppercorn MA (1992) Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol 87:609–612PubMedGoogle Scholar
  31. 31.
    Trespi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, De Vecchi P, Matti C (1999) Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Minerva Gastroenterol Dietol 45:245–252Google Scholar
  32. 32.
    Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34:510–515PubMedCrossRefGoogle Scholar
  33. 33.
    Di Mario F, Aragona G, Leandro G, et al. (2005) Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 50:581–586PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Giuseppe Comparato
    • 1
  • Libera Fanigliulo
    • 1
  • Lucas G Cavallaro
    • 1
  • Giovanni Aragona
    • 2
  • Giulia Martina Cavestro
    • 1
  • Veronica Iori
    • 1
  • Marta Maino
    • 1
  • Giancarlo Mazzocchi
    • 3
  • Pierantonio Muzzetto
    • 4
  • Giancarlo Colla
    • 4
  • Mario Sianesi
    • 5
  • Angelo Franzé
    • 4
  • Francesco Di. Mario
    • 1
    • 6
  1. 1.Department of Clinical SciencesChair of Gastroenterology, University of ParmaParmaItaly
  2. 2.Gastroenterology and Endoscopy Unit, Az. OspedalieraPiacenzaItaly
  3. 3.U.O. Chirurgia Borgovalditaro, AUSLParmaItaly
  4. 4.Gastroenterology and Endoscopy Unit, Az. OspedalieraParmaItaly
  5. 5.Department of General Surgery and Organ TransplantationUniversity of ParmaParmaItaly
  6. 6.Università degli Studi di Parma, Dipartimento di Scienze Cliniche, Sezione di GastroenterologiaParmaItaly

Personalised recommendations